Inhibition of breast cancer cell extracellular matrix degradative activity by chemically modified tetracyclines

Annals of Medicine

Volumn 37, Issue 6, 2005, Pages 450-460

  Gu, Ying ^a   Lee, Hsi Ming ^a   Golub, Lorne M ^a   Sorsa, Timo ^b   Konttinen, Yrjö T ^b,c,e   Simon, Sanford R ^a,d  

^a STONY BROOK UNIVERSITY   (United States)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c ORTON Orthopaedic Hospital of the Invalid Foundation ^*  (Finland)

^d STONY BROOK UNIVERSITY   (United States)

^e BIOMEDICUM HELSINKI   (Finland)

Author keywords

Chemically modified tetracycline; ECM degradation; Matrix metalloproteinase; MDA MB 231; Tumour metastasis

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; GELATINASE B; MATRIX METALLOPROTEINASE; TETRACYCLINE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOSTASIS; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; RAT; WESTERN BLOTTING; ZYMOGRAPHY;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GELATINASES; HUMANS; IMMUNOBLOTTING; MATRIX METALLOPROTEINASE 9; TETRACYCLINES; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 26944455184     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/07853890500300386     Document Type: Article

References (33)

1. Heppner KJ, Matrisian LM, Jensen RA, Rodgers WH. Expression of most matrix 1 metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol. 1996;149:273-82.
2. Dickson RB, Shi YE, Johnson MD. Matrix-degrading proteases in hormone-dependent breast cancer. Breast Cancer Res Treat. 1994;31:167-73.
3. Shinmei M, Masuda K, Kikuchi T, Shimomura YJ. The role of cytokines in chondrocyte mediated cartilage degradation. J Rheumatol Suppl. 1989;18:32-4.
4. Duncan MR, Berman B. Differential regulation of glycosaminoglycan, fibronectin, and collagenase production in cultured human dermal fibroblasts by interferon-alpha, -beta, and -gamma. Arch Dermatol Res. 1989;281:11-18.
5. Vollberg TM, George MD, Jetten AM. Induction of extracellular matrix gene expression in normal human keratinocytes by transforming growth factor beta is altered by cellular differentiation. Exp Cell Res. 1991;193:93-00.
6. Ahmadzadeh N, Shingu M, Nobunaga M. The effect of recombinant tumor necrosis factor-alpha on superoxide and metalloproteinase production by synovial cells and chondrocytes. Clin Exp Rheumatol. 1990;8:387-91.
7. Unemori EN, Hibbs MS, Amento EP. Constitutive expression of a 92-kD gelatinase (type V collagenase) by rheumatoid synovial fibroblasts and its induction in normal human fibroblasts by inflammatory cytokines. J Clin Invest. 1991;88:1656-62.
8. Owen CA, Hu Z, Lopez-Otin C, Shapiro SD. Membrane-bound matrix metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase-resistant collagenases and serpinase. J Immunol. 2004;172:7791-803.
9. Sorsa T, Golub LM. Is the excessive inhibition of matrix metalloproteinases (MMPs) by potent synthetic MMP inhibitors (MMPIs) desirable in periodontitis and other inflammatory diseases? ie., "leaky" MMPIs vs. excessively efficient drugs. Oral Dis. 2005; accepted for publication.
10. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998;12:12-26.
11. Zucker S, Lysik RM, Ramamurthy NS, Golub LM, Wieman JM, Wilkie DP. Diversity of melanoma plasma membrane proteinases: inhibition of collagenolytic and cytolytic activities by minocycline. J Natl Cancer Inst. 1985;75:517-25.
12. Zucker S, Wieman J, Lysik RM, Imhof B, Nagase H, Ramamurthy NS, et al. Gelatin-degrading type IV collagenase isolated from human small cell lung cancer. Invasion Metastasis. 1989;9:167-81.
13. Rifkin BR, Vernillo AT, Golub LM, Ramamurthy NS. Modulation of bone resorption by tetracyclines. Ann N Y Acad Sci. 1994;732:165-80.
14. Lokeshwar BL, Selzer MG, Zhu BQ, Block NL, Golub LM. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int J Cancer. 2002;98:297-309.
15. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem. 1999;274:13066-76.
16. Rinehart AR, Mallya S, Simon SR. Human alpha 1-proteinase inhibitor binds to extracellular matrix in vitro. Am J Respir Cell Mol Biol. 1993;9:666-79.
17. Gu Y, Lee HM, Roemer EJ, Musacchia L, Golub LM, Simon SR. Inhibition of tumor cell invasiveness by chemically modified tetracyclines. Curr Med Chem. 2001;8:261-70.
18. Roemer EJ, Stanton K, Simon SR. In vitro assay systems for cell interactions with intersititial extracellular matrix. In Vitro Toxicology. 1994;7:209-24.
19. Fidler IJ, Radinsky RJ. Genetic control of cancer metastasis. J Natl Cancer Inst. 1990;82:166-8.
20. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991;64:327-36.
21. Akiyama SK, Nagata K, Yamada KM. Cell surface receptors for extracellular matrix components. Biochim Biophys Acta. 1990;1031:91-110.
22. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69:11-25.
23. Kozlova NI, Morozevich GE, Soloveyva NI, Vinokurova SV, Berman AE. Integrin expression and collagenase activity of RSV-transformed Syrian hamster fibroblasts, differing in spontaneous metastasizing. Biochem Mol Biol Int. 1997;43:529-39.
24. Langholz O, Rockel D, Mauch C, Kozlowska E, Bank I, Krieg T, et al. Collagen and collagenase gene expression in three-dimensional collagen lattices are differentially regulated by alpha 1 beta 1 and alpha 2 beta 1 integrins. Cell Biol. 1995;131:1903-15.
25. Smith GN, Brandt KD, Hasty KA. Procollagenase is reduced to inactive fragments upon activation in the presence of doxycycline. Ann N Y Acad Sci. 1994;732:436-8.
26. Uitto VJ, Firth JD, Nip L, Golub LM. Doxycycline and chemically modified tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin keratinocytes. Ann N Y Acad Sci. 1994;732:140-51.
27. Mackay AR, Ballin M, Pelina MD, Farina AR, Nason AM, Hartzler JL, et al. Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines. Invasion Metastasis. 1992;12:168-84.
28. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson, et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature. 1994;370:555-7.
29. Mohler KM, Sleath PR, Fitzner JN, Cerretti DP, Alderson M, Kerwar SS, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature. 1994;370:218-20.
30. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature. 1997;385:733-6.
31. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385:729-33.
32. Amour A, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ, et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 1998;435:39-44.
33. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial. Nat Rev Cancer. 2002;2:657-72.